China's biggest biotech plots $2B IPO

Citing sources, Bloomberg is reporting that China National Biotec is planning a $2 billion IPO. The company is ranked as the largest biotech in China and the fourth largest vaccine-maker in the world. If all goes according to plan, the company's shares will start trading next year. Report

Suggested Articles

Keep your post-pandemic trials on track: learn how the right clinical supply chain partner can help sponsors avoid trial disruption. Read now>>

Helsinn Group and MEI Pharma penned a near $500 million biobucks pact for experimental blood cancer drug pracinostat back in 2016.

Novavax has brought new CMC head Machielse to head manufacturing; Rexgenero taps Wagener as CMO; EMA nominates Cooke as new director.